A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2016

At a glance

  • Drugs Cobimetinib (Primary) ; Dextromethorphan; Midazolam
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 16 Jul 2016 Results (n=97) published in the Investigational New Drugs
    • 10 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2015 Results assessing population pharmacokinetics from pooled data of MEK4592g, GO28141 and NO25395 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top